SFA
VRTX icon

Souders Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Souders Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23M Sell
2,471
-26
-1% -$11.5K 0.12% 89
2026
Q1 		$1.12M Buy
2,497
+491
+24% +$229K 0.13% 87
2025
Q4 		$909K Buy
2,006
+242
+14% +$104K 0.1% 94
2025
Q3 		$691K Buy
1,764
+455
+35% +$190K 0.08% 113
2025
Q2 		$583K Buy
1,309
+222
+20% +$102K 0.07% 124
2025
Q1 		$527K Sell
1,087
-60
-5% -$28K 0.07% 126
2024
Q4 		$462K Sell
1,147
-319
-22% -$148K 0.06% 129
2024
Q3 		$682K Buy
1,466
+30
+2% +$14.4K 0.1% 115
2024
Q2 		$673K Buy
1,436
+37
+3% +$16.1K 0.1% 112
2024
Q1 		$585K Buy
+1,399
New +$591K 0.09% 115

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Souders Financial Advisors's VRTX Position: Q2 2026 in Review

Souders Financial Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 1% in Q2 2026, selling an estimated $11.5K and leaving 2,471 shares worth $1.23M. The position accounts for 0.12% of the portfolio, ranked #89.

Souders Financial Advisors first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Souders Financial Advisors held 2,471 shares of Vertex Pharmaceuticals worth $1.23M as of Q2 2026.
  • Souders Financial Advisors sold 26 Vertex Pharmaceuticals shares in Q2 2026, an estimated $11.5K.
  • Vertex Pharmaceuticals made up 0.12% of Souders Financial Advisors's portfolio in Q2 2026, its #89 holding.
  • Souders Financial Advisors first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Souders Financial Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.